News Minimalist logo

PEMGARDATM shows continued effectiveness against dominant COVID variants

globenewswire.com — September 3, 2024, 12:00 PM UTC

Summary: Invivyd, Inc. announced that its investigational monoclonal antibody PEMGARDATM (pemivibart) continues to neutralize dominant SARS-CoV-2 variants KP.3.1.1 and LB.1, with KP.3.1.1 representing 42.2% of circulating variants in late August. The company submitted data to the FDA for updates to the PEMGARDA Healthcare Providers Fact Sheet, highlighting its ongoing efficacy against evolving viral strains.

Full article

Article metrics

The article metrics are deprecated.

I'm replacing the original 8-factor scoring system with a new and improved one. It doesn't use the original factors and gives much better significance scores.

Timeline:

  1. [3.6]
    ProKidney revises Phase 3 program for kidney disease treatment (seekingalpha.com)
    6d 11h
    Source
  2. [3.9]
    ProKidney refines Phase 3 program for U.S. rilparencel approval (benzinga.com)
    6d 14h
    Source
  3. [4.2]
    Unicycive submits NDA for Oxylanthanum Carbonate to FDA (globenewswire.com)
    6d 15h
    Source
  4. [4.1]
    ProKidney updates Phase 3 program for CKD treatment rilparencel (globenewswire.com)
    6d 15h
    Source
  5. [3.4]
    Corvus advances soquelitinib for relapsed PTCL therapy (seekingalpha.com)
    7d 15h
    Source